Optibrium Ltd.
This article was originally published in Start Up
Executive Summary
Drug development is difficult and risky, and the timescales are long. Optibrium Ltd. has developed StarDrop, a software platform designed to support drug discovery by guiding decisions in the design and selection of potential drug candidates based on complex and uncertain data. Through chemical space visualization, supported by a visualization tool and probabilistic scoring, StarDrop compares candidate molecules against a weighted profile of required properties, and helps users to identify chemistries with a high chance of success in order to better focus their expensive in-house resources.
You may also be interested in...
Start-Up Previews (02/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "New Antibody Platforms," features profiles of arGEN-X, Crescendo Biologics, Oligasis and Open Monoclonal Technology. Plus these Start-Ups Across Health Care: BioMarker Strategies, BMEYE, Clear Catheter Systesm, Epicardial Technologies and Optibrium.
Gadeta BV: Using T-Cells To Target Metabolic Dysregulation In Cancer
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.